uploads///bacteria _

What Analysts Recommend for AbbVie and Celgene This Month

By

Feb. 7 2019, Published 3:19 p.m. ET

Share price movements

On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77, and 34.68% lower than its 52-week high of $122. Its market cap was $127.82 billion, and its trailing-12-month and forward PE ratios were 15.69x and 8.33x, respectively.

After its fourth-quarter earnings release, AbbVie stock fell 7.21% from $85.88 on January 24 to $79.69 on February 5. The company missed analysts’ consensus revenue estimate by $60 million and analysts’ consensus EPS estimate by $0.04 in the quarter.

Article continues below advertisement

On February 5, Celgene (CELG) closed at $88.14, 0.65% higher than its previous closing price, 50.44% higher than its 52-week low of $58.59, and 12.10% lower than its 52-week high of $100.27. Its market cap was $61.87 billion, and its trailing-12-month and forward PE ratios were 15.83x and 8.46x, respectively.

Celgene surpassed analysts’ consensus revenue estimate by $50 million and analysts’ consensus EPS estimate by $0.07 in the fourth quarter.

AbbVie is trading at a lower trailing PE ratio and a lower forward PE ratio than Celgene.

Analysts’ recommendations and target prices

The 12-month consensus recommendation for AbbVie is a “hold,” while for Celgene, it’s a “buy.”

Of the 18 analysts covering AbbVie, three have given it “strong buys,” three have given it “buys,” nine have given it “holds,” two have given it “sells,” and one has given it a “strong sell.” Analysts’ 12-month target price on the stock is $93.88, 17.81% higher than its closing price on February 5. The highest target price estimate for the company is $130, and the lowest is $71.

Of the 21 analysts covering Celgene, four have given it “strong buys,” six have given it “buys,” and 11 have given it “holds.” Analysts’ 12-month target price is $100.35, 13.85% higher than its closing price on February 4. The highest target price estimate for the company is $135, and the lowest is $84.

Next, we’ll look at AbbVie’s and Celgene’s revenue growth trajectories.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.